(PharmaNewsWire.Com, February 27, 2018 ) The Global Biosimilars Market was priced USD 4,760.0 million in 2016 and calculable to be growing at a CAGR of 26.87% to achieve USD 19,154.5 million by 2022, as per the reports of Market Data Forecast. Biosimilars play a crucial role being one of the important sectors of the healthcare trade.
Biosimilars are formed by using living cells that treat sickness, by recombinant deoxyribonucleic acid technology and controlled organic phenomenon. Mostly, Biosimilars are derived from plants, bacteria, viruses, and animals. Biosimilars medicine is used in prevention and cure of varied diseases like growth hormone deficiency, chronic kidney disease, autoimmune diseases, arthritis, heart attacks, infectious disease, diabetes, cancer, and oncology. Rise in value and health care expenditures, and therefore the demand for price effective therapeutics solution has resulted in the growth of this market.
The worldwide Biosimilars Market is principally driven by factors like increasing occurrence of chronic diseases like cancer and diabetes, high priced patented medicine, rise in the growing demand for pharmaceutical medicine and markets as they offer a cheaper option for other biological and synthetic drugs, raising co-operation between the manufacturing corporations, Government support and initiatives, and lenient government laws.
However, the high price of reference products will increase the money burden on patients, and quality of the medicine depends on the cost, compensation of service suppliers, and ease of using the low priced generic medicine available within the market are foremost factors impeding the growth of the market.
The fragmentation of Global Biosimilars Market is done on the basis of type and application. On the idea of application, the Global Biosimilars Market is bifurcated as blood disorders, chronic diseases, oncology deficiency, autoimmune diseases, and growth hormone deficiency. On the origin of product types, the Biosimilars market is segregated into Monoclonal Antibodies, Glucagon, Human Growth Hormones, Recombinant Peptides, Interferons, Follitropin, Insulin, Recombinant Glycosylated Proteins, Erythropoietin, Protein, Calcitonin, Granulocyte Colony-stimulating Factor (G-CSF).
On the standard of geographical analysis, the worldwide Biosimilars Market is classified into varied regions namely Middle East, North America, Europe, Latin America, and Asia-Pacific, Africa. Europe is, without doubt, the biggest market, followed by North America and Asia-Pacific regions. India and China are calculable to grow the quickest. Countries like the U.S., Brazil and South Korea, are expected to record high growth over succeeding 5 years.
Some of the major share holders dominating the Biosimilars Market are Mylan Inc., Sandoz International GmbH, Cipla Ltd, Teva Pharmaceutical Industries Ltd, Wockhardt Ltd, Roche Diagnostics, Biocon Limited, Hospira Inc, Zydus Cadila, and Dr Reddy’s Laboratories, Celltrion Inc.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
